Neos Therapeutics (NASDAQ:NEOS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Several other research firms have also weighed in on NEOS. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research note on Wednesday, August 8th. Wells Fargo & Co lowered their price objective on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. ValuEngine upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Finally, JMP Securities lowered their price objective on shares of Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research note on Monday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $12.00.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Friday, November 9th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.03). The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $14.80 million. Neos Therapeutics had a negative net margin of 133.46% and a negative return on equity of 586.25%. On average, sell-side analysts forecast that Neos Therapeutics will post -1.77 earnings per share for the current year.
In related news, Director Alan L. Heller acquired 43,478 shares of the stock in a transaction dated Thursday, November 8th. The stock was bought at an average price of $2.30 per share, for a total transaction of $99,999.40. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in NEOS. Sphera Funds Management LTD. increased its stake in shares of Neos Therapeutics by 136.2% in the 3rd quarter. Sphera Funds Management LTD. now owns 831,697 shares of the company’s stock valued at $4,034,000 after acquiring an additional 479,555 shares in the last quarter. Nexthera Capital LP acquired a new stake in Neos Therapeutics in the 2nd quarter valued at $2,369,000. BlackRock Inc. grew its position in Neos Therapeutics by 13.9% in the 2nd quarter. BlackRock Inc. now owns 2,091,282 shares of the company’s stock valued at $13,070,000 after purchasing an additional 255,037 shares during the period. Stonepine Capital Management LLC acquired a new stake in Neos Therapeutics in the 3rd quarter valued at $1,105,000. Finally, Franklin Resources Inc. grew its position in Neos Therapeutics by 8.4% in the 3rd quarter. Franklin Resources Inc. now owns 2,493,239 shares of the company’s stock valued at $12,092,000 after purchasing an additional 193,500 shares during the period. Institutional investors own 45.99% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Read More: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.